Results 31 to 40 of about 20,820 (198)

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage

International Journal of Infectious Diseases, 2019
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir, and after being administered orally, it converts to tenofovir in the blood. With the increasing use of TDF in women for treatment and prevention of mother-to-child transmission (MTCT) of both
Xiaotong Hu, Liming Wang, Fujie Xu
doaj   +1 more source

Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. [PDF]

, 2011
The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings.
Birkus, Brinkman, Callaghan, Cohen, Davidson, Ford, Gallant, Gallant, Grim, Hawkins, Mills, Pozniak, Stone   +12 more
core   +2 more sources

Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion

International Journal of Infectious Diseases, 2020
Failure of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine may occur despite perfect adherence, although this is uncommon. Failure results in breakthrough HIV infection.
Shui-Shan Lee, Peter L. Anderson, Tsz-Ho Kwan, Grace C.Y. Lui, Denise P.C. Chan, Ngai-Sze Wong, Krystal C.K. Lee, Teddy T.N. Lam   +7 more
doaj   +1 more source

Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study

The Lancet Global Health, 2021
Summary: Background: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective childhood vaccines.
Peyton Thompson, MD, Camille E Morgan, BSPH, Patrick Ngimbi, MD, Kashamuka Mwandagalirwa, MSPH, Noro L R Ravelomanana, MD, Martine Tabala, MLT, Malongo Fathy, MD, Bienvenu Kawende, MD, Jérémie Muwonga, PhD, Pacifique Misingi, MD, Charles Mbendi, MD, Christophe Luhata, MD, Ravi Jhaveri, MD, Gavin Cloherty, PhD, Didine Kaba, ProfPhD, Marcel Yotebieng, PhD, Jonathan B Parr, MD   +16 more
doaj   +1 more source

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report

Journal of Medical Case Reports, 2009
Introduction Tenofovir disoproxil fumarate (Viread®) is the only nucleotide reverse transcriptase inhibitor currently approved for the treatment of HIV. It is frequently prescribed not only for its efficacy but also for its decreased side effect profile ...
Di Biagio Antonio, Rosso Raffaella, Monteforte Patrizia, Russo Rodolfo, Rovetta Guido, Viscoli Claudio   +5 more
doaj   +1 more source

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. [PDF]

, 2007
BackgroundWe reported previously on the emergence and clinical implications of simian immunodeficiency virus (SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune responses in suppressing ...
Bischofberger, Norbert, Blackwood, Emily J, Heneine, Walid, Johnson, Jeffrey A, Lipscomb, Jonathan, Marthas, Marta L, Matthews, Timothy B, North, Thomas W, Pedersen, Niels C, Singh, Raman P, Van Rompay, Koen KA   +10 more
core   +3 more sources

Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation

The Scientific World Journal, 2012
A stability-indicating high-performance thin-layer chromatographic (HPTLC) method for determination of tenofovir disoproxil fumarate in bulk drug and in tablet has been developed and validated. The mobile phase selected was chloroform : methanol (9.0 : 1.
Shweta Havele, Sunil R. Dhaneshwar
doaj   +1 more source

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults

Journal of Infection and Public Health, 2015
Summary: This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011.PubMed, Cochrane and
Wissam K. Kabbara, Wijdan H. Ramadan
doaj   +1 more source